KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Assets Average (2016 - 2025)

Travere Therapeutics' Assets Average history spans 15 years, with the latest figure at $571.9 million for Q4 2025.

  • For Q4 2025, Assets Average rose 4.12% year-over-year to $571.9 million; the TTM value through Dec 2025 reached $571.9 million, up 4.12%, while the annual FY2025 figure was $599.7 million, 13.28% down from the prior year.
  • Assets Average reached $571.9 million in Q4 2025 per TVTX's latest filing, up from $546.9 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $810.9 million in Q4 2023 to a low of $527.8 million in Q3 2024.
  • Average Assets Average over 5 years is $689.9 million, with a median of $733.3 million recorded in 2023.
  • Peak YoY movement for Assets Average: increased 20.7% in 2021, then crashed 32.74% in 2024.
  • A 5-year view of Assets Average shows it stood at $775.9 million in 2021, then decreased by 9.85% to $699.4 million in 2022, then rose by 15.94% to $810.9 million in 2023, then tumbled by 32.26% to $549.3 million in 2024, then grew by 4.12% to $571.9 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Assets Average are $571.9 million (Q4 2025), $546.9 million (Q3 2025), and $552.1 million (Q2 2025).